232 related articles for article (PubMed ID: 30913329)
21. Amphiphilic Gemini Iridium(III) Complex as a Mitochondria-Targeted Theranostic Agent for Tumor Imaging and Photodynamic Therapy.
Yi S; Lu Z; Zhang J; Wang J; Xie Z; Hou L
ACS Appl Mater Interfaces; 2019 May; 11(17):15276-15289. PubMed ID: 30968687
[TBL] [Abstract][Full Text] [Related]
22. Near-infrared emitting iridium(iii) complexes for mitochondrial imaging in living cells.
Liu Y; Zhang P; Fang X; Wu G; Chen S; Zhang Z; Chao H; Tan W; Xu L
Dalton Trans; 2017 Apr; 46(14):4777-4785. PubMed ID: 28345088
[TBL] [Abstract][Full Text] [Related]
23. Photoinduced anticancer activity studies of iridium(III) complexes targeting mitochondria and tubules.
Zhang WY; Yi QY; Wang YJ; Du F; He M; Tang B; Wan D; Liu YJ; Huang HL
Eur J Med Chem; 2018 May; 151():568-584. PubMed ID: 29656200
[TBL] [Abstract][Full Text] [Related]
24. Iridium (III) complexes induce cervical carcinoma apoptosis via disturbing cellular redox homeostasis disorder and inhibiting PI3K/AKT/mTOR pathway.
Hao J; Liu H; Wang J; Wang X; Huang C; Liang L; Chen J; Wang Y; Liu Y
J Inorg Biochem; 2022 Oct; 235():111946. PubMed ID: 35932758
[TBL] [Abstract][Full Text] [Related]
25. Iridium(III) complexes entrapped in liposomes trigger mitochondria-mediated apoptosis and GSDME-mediated pyroptosis.
Zhang H; Liao X; Wu X; Shi C; Zhang Y; Yuan Y; Li W; Wang J; Liu Y
J Inorg Biochem; 2022 Mar; 228():111706. PubMed ID: 35033830
[TBL] [Abstract][Full Text] [Related]
26. Study on the Multimodal Anticancer Mechanism of Ru(II)/Ir(III) Complexes Bearing a Poly(ADP-ribose) Polymerase 1 Inhibitor.
Yang Y; Gao Y; Sun Y; Zhao J; Gou S
J Med Chem; 2023 Oct; 66(19):13731-13745. PubMed ID: 37788351
[TBL] [Abstract][Full Text] [Related]
27. Dual inhibition of oxidative phosphorylation and glycolysis to enhance cancer therapy.
Sheng X; Wang MM; Zhang GD; Su Y; Fang HB; Yu ZH; Su Z
Bioorg Chem; 2024 Jun; 147():107325. PubMed ID: 38583247
[TBL] [Abstract][Full Text] [Related]
28. Single-Cell Quantification of a Highly Biocompatible Dinuclear Iridium(III) Complex for Photocatalytic Cancer Therapy.
Fan Z; Rong Y; Sadhukhan T; Liang S; Li W; Yuan Z; Zhu Z; Guo S; Ji S; Wang J; Kushwaha R; Banerjee S; Raghavachari K; Huang H
Angew Chem Int Ed Engl; 2022 Jun; 61(23):e202202098. PubMed ID: 35258153
[TBL] [Abstract][Full Text] [Related]
29. Highly Efficient Ir(III)-Coumarin Photo-Redox Catalyst for Synergetic Multi-Mode Cancer Photo-Therapy.
Fan Z; Xie J; Sadhukhan T; Liang C; Huang C; Li W; Li T; Zhang P; Banerjee S; Raghavachari K; Huang H
Chemistry; 2022 Jan; 28(3):e202103346. PubMed ID: 34755401
[TBL] [Abstract][Full Text] [Related]
30. Coumarin-appended phosphorescent cyclometalated iridium(iii) complexes as mitochondria-targeted theranostic anticancer agents.
Ye RR; Tan CP; Ji LN; Mao ZW
Dalton Trans; 2016 Aug; 45(33):13042-51. PubMed ID: 27139504
[TBL] [Abstract][Full Text] [Related]
31. Photocatalytic glucose-appended bio-compatible Ir(III) anticancer complexes.
Zhu Z; Wei L; Lai Y; Carter OWL; Banerjee S; Sadler PJ; Huang H
Dalton Trans; 2022 Jul; 51(29):10875-10879. PubMed ID: 35796219
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, photophysical and anticancer properties of mitochondria-targeted phosphorescent cyclometalated iridium(III) N-heterocyclic carbene complexes.
Li Y; Wang KN; He L; Ji LN; Mao ZW
J Inorg Biochem; 2020 Apr; 205():110976. PubMed ID: 31926377
[TBL] [Abstract][Full Text] [Related]
33. Organometallic Iridium(III) anticancer complexes with new mechanisms of action: NCI-60 screening, mitochondrial targeting, and apoptosis.
Hearn JM; Romero-Canelón I; Qamar B; Liu Z; Hands-Portman I; Sadler PJ
ACS Chem Biol; 2013; 8(6):1335-43. PubMed ID: 23618382
[TBL] [Abstract][Full Text] [Related]
34. Ester-Modified Cyclometalated Iridium(III) Complexes as Mitochondria-Targeting Anticancer Agents.
Wang FX; Chen MH; Hu XY; Ye RR; Tan CP; Ji LN; Mao ZW
Sci Rep; 2016 Dec; 6():38954. PubMed ID: 27958338
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, characterization and anticancer activity in vitro and in vivo evaluation of an iridium (III) polypyridyl complex.
Yi QY; Wan D; Tang B; Wang YJ; Zhang WY; Du F; He M; Liu YJ
Eur J Med Chem; 2018 Feb; 145():338-349. PubMed ID: 29331805
[TBL] [Abstract][Full Text] [Related]
36. Alkyl chain-modified cyclometalated iridium complexes as tunable anticancer and imaging agents.
Laha P; De U; Chandra F; Dehury N; Khullar S; Kim HS; Patra S
Dalton Trans; 2018 Nov; 47(44):15873-15881. PubMed ID: 30358775
[TBL] [Abstract][Full Text] [Related]
37. In-vitro and In-vivo Photocatalytic Cancer Therapy with Biocompatible Iridium(III) Photocatalysts.
Huang C; Liang C; Sadhukhan T; Banerjee S; Fan Z; Li T; Zhu Z; Zhang P; Raghavachari K; Huang H
Angew Chem Int Ed Engl; 2021 Apr; 60(17):9474-9479. PubMed ID: 33434379
[TBL] [Abstract][Full Text] [Related]
38. Valproic Acid-Functionalized Cyclometalated Iridium(III) Complexes as Mitochondria-Targeting Anticancer Agents.
Ye RR; Cao JJ; Tan CP; Ji LN; Mao ZW
Chemistry; 2017 Oct; 23(60):15166-15176. PubMed ID: 28833658
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and anticancer activity in vitro and in vivo evaluation of iridium(III) complexes on mouse melanoma B16 cells.
Yuan Y; Shi C; Wu X; Li W; Huang C; Liang L; Chen J; Wang Y; Liu Y
J Inorg Biochem; 2022 Jul; 232():111820. PubMed ID: 35421766
[TBL] [Abstract][Full Text] [Related]
40. Potential anticancer agent for selective damage to mitochondria or lysosomes: Naphthalimide-modified fluorescent biomarker half-sandwich iridium (III) and ruthenium (II) complexes.
Ma W; Zhang S; Tian Z; Xu Z; Zhang Y; Xia X; Chen X; Liu Z
Eur J Med Chem; 2019 Nov; 181():111599. PubMed ID: 31408807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
